NCT04254783 - A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

October 14, 2022

Study Completion Date

October 14, 2022

Conditions

Ulcerative Colitis (UC)Crohn's Disease

Interventions

DRUG

Risankizumab

Intravenous (IV) infusion

DRUG

Cytochrome P450 (CYP) Substrates

Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol

Trial Locations (6)

Charite Research Organisation GmbH /ID# 218646, Berlin

University Clinical Research /ID# 216823, DeLand

Clinical Trials of Texas, Inc /ID# 216277, San Antonio

The Chaim Sheba Medical Center /ID# 223959, Ramat Gan

Southern California Res. Ctr. /ID# 216257, Coronado

Atlantic Medical Research Group /ID# 227465, Margate